Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 219,400 shares, a growth of 11.7% from the March 31st total of 196,400 shares. Based on an average trading volume of 91,100 shares, the days-to-cover ratio is currently 2.4 days. Currently, 1.7% of the company’s shares are sold short.

Affimed Trading Up 9.1 %

AFMD opened at $5.49 on Tuesday. The firm’s 50 day moving average is $5.45 and its 200-day moving average is $5.03. Affimed has a 52-week low of $2.23 and a 52-week high of $11.10. The company has a quick ratio of 3.23, a current ratio of 3.25 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $83.60 million, a P/E ratio of -0.65 and a beta of 2.05.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AFMD shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. Wells Fargo & Company reduced their price target on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, April 1st. StockNews.com started coverage on shares of Affimed in a research report on Tuesday, January 2nd. They issued a “sell” rating for the company. Finally, HC Wainwright lifted their target price on shares of Affimed to $10.00 and gave the company a “buy” rating in a report on Monday, April 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, Affimed currently has an average rating of “Moderate Buy” and an average target price of $45.00.

Institutional Investors Weigh In On Affimed

Large investors have recently added to or reduced their stakes in the company. Vestal Point Capital LP purchased a new position in Affimed in the 4th quarter valued at about $341,000. abrdn plc acquired a new position in shares of Affimed in the fourth quarter worth about $130,000. BNP Paribas Financial Markets boosted its holdings in Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 163,162 shares during the last quarter. Finally, EWA LLC acquired a new stake in Affimed during the 4th quarter valued at approximately $89,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.